News
ASH: Lilly builds case for its BTK drug LOXO-305 in lymphoma
Eli Lilly’s buyout of Loxo Oncology last year has already yielded one approved drug, and it now has a path to market for a second after BTK inhibitor LOXO-305 after reporting promising data
